Research
Hormonal
Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, intraglomerular hypertension, and direct adipose tissue endocrine effects, independent of diabetes and hypertension.
High body weight, particularly visceral fat, directly stresses the kidneys through increased pressure and inflammatory signals, leading to chronic kidney disease even without diabetes. Managing weight through lifestyle changes is a primary strategy to prevent kidney damage.
GoodSupportsHIGH confidence
In individuals affected by obesity, a (likely) compensatory mechanism of hyperfiltration occurs to meet the heightened metabolic demands of the increased bodyweight. The increase in intraglomerular pressure can damage the kidney structure and raise the risk of developing CKD in the long-term.
Why this rating
Based on numerous population-based studies, meta-analyses, and consistent observational data, though exact mechanisms are described as 'unclear'.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Internal Medicine Journal · 2017
DOI 10.1111/imj.13342
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions (caloric restriction and physical activity) reduce the risk of incident chronic kidney disease in obese diabetic patients by approximately 30% compared to standard care.Good
- In patients with advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD), higher BMI is paradoxically associated with lower mortality rates, likely due to nutritional reserves and muscle mass.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →